Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALONZO E JONES

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1952389991
CMS profile
418907
Location
COLUMBUS, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$448.72

36 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $448.72 36

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALONZO E JONES

NPI 1952389991 · CMS profile ID 418907

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

COLUMBUS, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1952389991?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALONZO E JONES, NPI 1952389991, CMS profile ID 418907. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1952389991?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ALONZO E JONES, NPI 1952389991, CMS profile ID 418907. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1952389991?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ALONZO E JONES, NPI 1952389991, CMS profile ID 418907, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–36 of 36 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1952389991?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

36 matching records · $448.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 36 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–36 of 36.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Esperion Therapeutics, Inc. $18.1312/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737213649 CMS
Janssen Pharmaceuticals, Inc $13.3112/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718967937 CMS
Abbott Laboratories $14.3412/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742537909 CMS
Novartis Pharmaceuticals Corporation $12.5212/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725837939 CMS
Janssen Pharmaceuticals, Inc $16.2711/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718967929 CMS
Novartis Pharmaceuticals Corporation $12.3211/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725837927 CMS
Janssen Pharmaceuticals, Inc $2.1511/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718967917 CMS
Janssen Pharmaceuticals, Inc $15.2611/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718967925 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $13.4010/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723101477 CMS
Novartis Pharmaceuticals Corporation $16.7310/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725837933 CMS
AstraZeneca Pharmaceuticals LP $13.7410/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736392479 CMS
Janssen Pharmaceuticals, Inc $5.3310/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718967909 CMS
Novartis Pharmaceuticals Corporation $12.8910/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725837919 CMS
Esperion Therapeutics, Inc. $11.2609/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737213645 CMS
Janssen Pharmaceuticals, Inc $11.4109/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718967895 CMS
Janssen Pharmaceuticals, Inc $5.6608/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718967887 CMS
Abbott Laboratories $22.2707/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746584025 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $13.8407/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723101475 CMS
Novartis Pharmaceuticals Corporation $13.6607/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725837915 CMS
Janssen Pharmaceuticals, Inc $9.1107/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718967903 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $11.1307/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723101483 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $13.3406/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723101479 CMS
Janssen Pharmaceuticals, Inc $5.1706/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718967873 CMS
Amgen Inc. $13.3806/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740894271 CMS
Novartis Pharmaceuticals Corporation $14.9506/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725837911 CMS
Amgen Inc. $13.9205/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740894267 CMS
Janssen Pharmaceuticals, Inc $11.5705/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718967881 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $13.2005/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723101481 CMS
Amgen Inc. $21.9403/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740894265 CMS
Novartis Pharmaceuticals Corporation $14.4703/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725837905 CMS
Janssen Pharmaceuticals, Inc $9.3802/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718967867 CMS
PFIZER INC. $2.3502/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743314075 CMS
Amgen Inc. $13.8202/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741364721 CMS
Novartis Pharmaceuticals Corporation $17.7802/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725837899 CMS
Janssen Pharmaceuticals, Inc $6.7701/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718967859 CMS
Novartis Pharmaceuticals Corporation $11.9501/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725837893 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $559.09 41
PY2020 $448.72 36
PY2021 $570.20 38
PY2022 $625.57 30
PY2023 $1,200.24 49
PY2024 $830.59 35
PY2025 $831.80 31

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $24,416.95 19
PY2022 Principal investigator $89,144.80 16
PY2021 Principal investigator $140,262.94 64
PY2020 Recipient $20,304.24 16
PY2020 Principal investigator $97,368.42 58
PY2019 Recipient $20,304.24 16
PY2019 Principal investigator $57,349.01 39

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

55 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amgen Inc. $1,274.00 12/25/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
GALACTIC-HF No dispute reported 06/30/2026 675778717
Recipient Vifor (International) Ltd. $1,197.76 12/12/2019 Covered Recipient Physician DIAMOND PAT-CR-302 No dispute reported 06/30/2026 698421721
Recipient Vifor (International) Ltd. $1,197.76 12/05/2019 Covered Recipient Physician DIAMOND PAT-CR-302 No dispute reported 06/30/2026 698421707
Recipient Vifor (International) Ltd. $2,925.10 12/05/2019 Covered Recipient Physician DIAMOND PAT-CR-302 No dispute reported 06/30/2026 698421709
Recipient Vifor (International) Ltd. $1,197.76 12/05/2019 Covered Recipient Physician DIAMOND PAT-CR-302 No dispute reported 06/30/2026 698421713
Recipient Vifor (International) Ltd. $1,197.76 12/05/2019 Covered Recipient Physician DIAMOND PAT-CR-302 No dispute reported 06/30/2026 698421717
Recipient Vifor (International) Ltd. $2,925.10 12/05/2019 Covered Recipient Physician DIAMOND PAT-CR-302 No dispute reported 06/30/2026 698421723
Recipient Vifor (International) Ltd. $21.00 12/05/2019 Covered Recipient Physician DIAMOND PAT-CR-302 No dispute reported 06/30/2026 698421763
Recipient Vifor (International) Ltd. $21.00 11/21/2019 Covered Recipient Physician DIAMOND PAT-CR-302 No dispute reported 06/30/2026 698421761
Principal investigator 1 Array BioPharma Inc. $75.00 11/08/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704870343
Principal investigator 1 Array BioPharma Inc. $110.00 11/08/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704870345
Recipient Vifor (International) Ltd. $21.00 11/08/2019 Covered Recipient Physician DIAMOND PAT-CR-302 No dispute reported 06/30/2026 698421757
Principal investigator 1 Merck Sharp & Dohme Corporation $8,000.00 10/09/2019 Non-covered Recipient Entity
COLUMBUS CARDIOLOGY ASSOCIATES RESEARCH
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA No dispute reported 06/30/2026 691448363
Principal investigator 1 Array BioPharma Inc. $4,000.00 10/04/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704870341
Recipient Vifor (International) Ltd. $50.00 10/04/2019 Covered Recipient Physician DIAMOND PAT-CR-302 No dispute reported 06/30/2026 698421741
Principal investigator 1 Merck Sharp & Dohme Corporation $1,970.60 09/11/2019 Non-covered Recipient Entity
COLUMBUS CARDIOLOGY ASSOCIATES RESEARCH
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA No dispute reported 06/30/2026 691373973
Recipient Vifor (International) Ltd. $1,500.00 09/06/2019 Covered Recipient Physician DIAMOND PAT-CR-302 No dispute reported 06/30/2026 698421727
Recipient Vifor (International) Ltd. $300.00 09/06/2019 Covered Recipient Physician DIAMOND PAT-CR-302 No dispute reported 06/30/2026 698421731
Recipient Vifor (International) Ltd. $1,200.00 09/06/2019 Covered Recipient Physician DIAMOND PAT-CR-302 No dispute reported 06/30/2026 698421733
Recipient Vifor (International) Ltd. $750.00 09/06/2019 Covered Recipient Physician DIAMOND PAT-CR-302 No dispute reported 06/30/2026 698421743
Recipient Vifor (International) Ltd. $800.00 09/06/2019 Covered Recipient Physician DIAMOND PAT-CR-302 No dispute reported 06/30/2026 698421747
Recipient Vifor (International) Ltd. $5,000.00 09/06/2019 Covered Recipient Physician DIAMOND PAT-CR-302 No dispute reported 06/30/2026 698421751
Principal investigator 1 Array BioPharma Inc. $429.00 09/05/2019 Non-covered Recipient Entity
The Copernicus Group
A Study of ARRY-371797 in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704870845
Principal investigator 1 Merck Sharp & Dohme Corporation $1,588.18 08/30/2019 Non-covered Recipient Entity
COLUMBUS CARDIOLOGY ASSOCIATES RESEARCH
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA No dispute reported 06/30/2026 691373969
Principal investigator 1 Merck Sharp & Dohme Corporation $372.00 08/30/2019 Non-covered Recipient Entity
COLUMBUS CARDIOLOGY ASSOCIATES RESEARCH
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA No dispute reported 06/30/2026 691452031
Principal investigator 1 Array BioPharma Inc. $212.00 08/28/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704870339
Principal investigator 1 Amgen Inc. $107.18 07/10/2019 Non-covered Recipient Entity
COLUMBUS CARDIOLOGY RESEARCH
GALACTIC-HF No dispute reported 06/30/2026 675784657
Principal investigator 1 Array BioPharma Inc. $636.00 07/10/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704870337
Principal investigator 1 Array BioPharma Inc. $1,518.75 07/01/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704870327
Principal investigator 1 Array BioPharma Inc. $1,012.50 07/01/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704870329
Principal investigator 1 Array BioPharma Inc. $506.25 07/01/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704870331
Principal investigator 1 Array BioPharma Inc. $162.00 07/01/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704870333
Principal investigator 1 Array BioPharma Inc. $424.00 07/01/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704870335
Principal investigator 1 Array BioPharma Inc. $2,240.00 06/21/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704871047
Principal investigator 1 Array BioPharma Inc. $2,750.00 06/21/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704871049
Principal investigator 1 Array BioPharma Inc. $42.00 06/19/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704871037
Principal investigator 1 Array BioPharma Inc. $100.00 06/19/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704871039
Principal investigator 1 Array BioPharma Inc. $324.00 06/19/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704871041
Principal investigator 1 Array BioPharma Inc. $1,012.50 06/19/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704871043
Principal investigator 1 Array BioPharma Inc. $21.00 06/19/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704871045
Principal investigator 1 Array BioPharma Inc. $42.00 06/14/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704871029
Principal investigator 1 Array BioPharma Inc. $506.25 06/14/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704871031
Principal investigator 1 Array BioPharma Inc. $63.00 06/14/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704871033
Principal investigator 1 Array BioPharma Inc. $63.00 06/14/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704871035
Principal investigator 1 Array BioPharma Inc. $50.00 05/16/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704871027
Principal investigator 1 Array BioPharma Inc. $736.00 05/02/2019 Non-covered Recipient Entity
The Copernicus Group
A Study of ARRY-371797 in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation No dispute reported 06/30/2026 704870835
Principal investigator 1 Merck Sharp & Dohme Corporation $1,120.70 05/01/2019 Non-covered Recipient Entity
COLUMBUS CARDIOLOGY ASSOCIATES RESEARCH
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA No dispute reported 06/30/2026 691313793
Principal investigator 1 Merck Sharp & Dohme Corporation $2,304.25 04/12/2019 Non-covered Recipient Entity
COLUMBUS CARDIOLOGY ASSOCIATES RESEARCH
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA No dispute reported 06/30/2026 691325775
Principal investigator 1 Amgen Inc. $1,095.00 03/28/2019 Non-covered Recipient Entity
COLUMBUS CARDIOLOGY RESEARCH
GALACTIC-HF No dispute reported 06/30/2026 675784651
Principal investigator 1 Merck Sharp & Dohme Corporation $1,011.34 03/04/2019 Non-covered Recipient Entity
COLUMBUS CARDIOLOGY ASSOCIATES RESEARCH
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA No dispute reported 06/30/2026 691313791
Principal investigator 1 Amgen Inc. $3,758.96 02/25/2019 Non-covered Recipient Entity
COLUMBUS CARDIOLOGY RESEARCH
GALACTIC-HF No dispute reported 06/30/2026 675784653
Principal investigator 1 Amgen Inc. $14,522.00 01/29/2019 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
GALACTIC-HF No dispute reported 06/30/2026 675784677
Principal investigator 1 Merck Sharp & Dohme Corporation $1,991.60 01/24/2019 Non-covered Recipient Entity
COLUMBUS CARDIOLOGY ASSOCIATES RESEARCH
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA No dispute reported 06/30/2026 691306809
Principal investigator 1 Merck Sharp & Dohme Corporation $1,120.70 01/15/2019 Non-covered Recipient Entity
COLUMBUS CARDIOLOGY ASSOCIATES RESEARCH
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA No dispute reported 06/30/2026 691306801
Principal investigator 1 Amgen Inc. $77.25 01/01/2019 Non-covered Recipient Entity
COLUMBUS CARDIOLOGY RESEARCH
GALACTIC-HF No dispute reported 06/30/2026 675784655